Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 95 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 1.44 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $780,815 | +41543.5% | 64,637 | -43.9% | 0.00% | -66.7% |
| Q1 2024 | $1,875 | +57.3% | 115,300 | -34.0% | 0.00% | +50.0% |
| Q4 2023 | $1,192 | -7.7% | 174,800 | -26.3% | 0.00% | 0.0% |
| Q3 2023 | $1,292 | -12.0% | 237,090 | +9.7% | 0.00% | 0.0% |
| Q2 2023 | $1,468 | +235.2% | 216,200 | +147.4% | 0.00% | +100.0% |
| Q1 2023 | $438 | +67.8% | 87,400 | +63.4% | 0.00% | – |
| Q4 2022 | $261 | -100.0% | 53,500 | -58.2% | 0.00% | -100.0% |
| Q3 2022 | $1,844,000 | -18.6% | 127,900 | -14.6% | 0.00% | 0.0% |
| Q2 2022 | $2,266,000 | +109.6% | 149,800 | +64.6% | 0.00% | +200.0% |
| Q1 2022 | $1,081,000 | -32.4% | 91,000 | -7.7% | 0.00% | -50.0% |
| Q4 2021 | $1,598,000 | +64.1% | 98,600 | +206.2% | 0.00% | +100.0% |
| Q1 2021 | $974,000 | +19.8% | 32,200 | +23.8% | 0.00% | 0.0% |
| Q4 2019 | $813,000 | -55.9% | 26,000 | -63.2% | 0.00% | -50.0% |
| Q3 2019 | $1,842,000 | +92.7% | 70,700 | +69.1% | 0.00% | +100.0% |
| Q2 2019 | $956,000 | – | 41,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,757,000 | 9.37% |
| Sofinnova Investments, Inc. | 2,194,278 | $31,641,000 | 1.84% |
| MPM BioImpact LLC | 443,702 | $6,398,000 | 1.52% |
| Artal Group S.A. | 400,000 | $5,768,000 | 0.25% |
| Polar Capital Holdings Plc | 2,531,546 | $36,505,000 | 0.23% |
| ASHFORD CAPITAL MANAGEMENT INC | 101,970 | $1,470,000 | 0.22% |
| Lombard Odier Asset Management (Switzerland) SA | 168,795 | $2,434,000 | 0.21% |
| Soleus Capital Management, L.P. | 87,182 | $1,257,000 | 0.17% |
| Cormorant Asset Management, LP | 150,000 | $2,163,000 | 0.15% |
| Walleye Capital LLC | 437,344 | $6,307,000 | 0.12% |